G S Gerber1. 1. Section of Urology, Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.
Abstract
PURPOSE: A comprehensive review of the literature on the use of saw palmetto in men with lower urinary tract symptoms is provided. MATERIALS AND METHODS: A literature search of studies that have assessed the mechanism of action and clinical results of saw palmetto in men with benign prostatic hyperplasia was performed. RESULTS: A variety of potential mechanisms of action of saw palmetto have been demonstrated through in vitro studies, including 5-alpha reductase inhibition, adrenergic receptor antagonism and intraprostatic androgen receptor blockade. Clinical evidence of the relevance of these effects is largely unavailable. The use of saw palmetto in men with benign prostatic hyperplasia is safe with no recognized adverse effects. No effect on serum prostate specific antigen has been noted. Placebo controlled trials and meta-analyses have suggested that saw palmetto leads to subjective and objective improvement in men with lower urinary tract symptoms. However, most studies are significantly limited by methodological flaws, small patient numbers and brief treatment intervals. CONCLUSIONS: Evidence suggests that saw palmetto may have a significant effect on urinary flow rates and symptom scores compared to placebo in men with lower urinary tract symptoms. However, large scale, placebo controlled trials are needed to assess the efficacy of saw palmetto.
PURPOSE: A comprehensive review of the literature on the use of saw palmetto in men with lower urinary tract symptoms is provided. MATERIALS AND METHODS: A literature search of studies that have assessed the mechanism of action and clinical results of saw palmetto in men with benign prostatic hyperplasia was performed. RESULTS: A variety of potential mechanisms of action of saw palmetto have been demonstrated through in vitro studies, including 5-alpha reductase inhibition, adrenergic receptor antagonism and intraprostatic androgen receptor blockade. Clinical evidence of the relevance of these effects is largely unavailable. The use of saw palmetto in men with benign prostatic hyperplasia is safe with no recognized adverse effects. No effect on serum prostate specific antigen has been noted. Placebo controlled trials and meta-analyses have suggested that saw palmetto leads to subjective and objective improvement in men with lower urinary tract symptoms. However, most studies are significantly limited by methodological flaws, small patient numbers and brief treatment intervals. CONCLUSIONS: Evidence suggests that saw palmetto may have a significant effect on urinary flow rates and symptom scores compared to placebo in men with lower urinary tract symptoms. However, large scale, placebo controlled trials are needed to assess the efficacy of saw palmetto.
Authors: Michael J Barry; Sreelatha Meleth; Jeannette Y Lee; Karl J Kreder; Andrew L Avins; J Curtis Nickel; Claus G Roehrborn; E David Crawford; Harris E Foster; Steven A Kaplan; Andrew McCullough; Gerald L Andriole; Michael J Naslund; O Dale Williams; John W Kusek; Catherine M Meyers; Joseph M Betz; Alan Cantor; Kevin T McVary Journal: JAMA Date: 2011-09-28 Impact factor: 56.272
Authors: Jeannette Lee; Gerald Andriole; Andrew Avins; E David Crawford; Harris Foster; Steven Kaplan; Karl Kreder; John Kusek; Andrew McCullough; Kevin McVary; Sreelatha Meleth; Michael Naslund; J Curtis Nickel; Leroy Nyberg; Claus Roehrborn; O Dale Williams; Michael Barry Journal: Clin Trials Date: 2009-12-09 Impact factor: 2.486
Authors: Gerald L Andriole; Christie McCullum-Hill; Gurdarshan S Sandhu; E David Crawford; Michael J Barry; Alan Cantor Journal: J Urol Date: 2012-12-14 Impact factor: 7.450
Authors: Robert Krochmal; Mary Hardy; Susan Bowerman; Qing-Yi Lu; H-J Wang; Rm Elashoff; David Heber Journal: Evid Based Complement Alternat Med Date: 2004-10-06 Impact factor: 2.629